Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Andrew B. Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F. Cloughesy, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 11, pp. 2270-2277
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Glioma
Michael Weller, Patrick Y. Wen, Susan M. Chang, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 104
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
Recurrent Glioblastoma: A Review of the Treatment Options
Maria Angeles Vaz-Salgado, María Villamayor, Víctor Albarrán, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4279-4279
Open Access | Times Cited: 44
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 43
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 17
Principles in the Management of Glioblastoma
Domingos Sanchez Roda, Pedro Veiga, Joana Barbosa Melo, et al.
Genes (2024) Vol. 15, Iss. 4, pp. 501-501
Open Access | Times Cited: 15
Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects
Zhipeng Cao, Sadia Quazi, Sakshi Arora, et al.
Journal of Biomedical Science (2025) Vol. 32, Iss. 1
Open Access | Times Cited: 4
From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress
Brittany Dewdney, Misty R. Jenkins, Sarah A. Best, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 34
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion
Alice Métais, Arnault Tauziède‐Espariat, Jeremy Garcia, et al.
Acta Neuropathologica Communications (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 19
Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors
Xiaopeng Guo, Yixin Shi, Delin Liu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 19
Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Estela Pineda, Marta Domènech, Ainhoa Hernández, et al.
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 71-86
Open Access | Times Cited: 18
Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis
Marta Padovan, Marta Maccari, Alberto Bosio, et al.
European Journal of Cancer (2023) Vol. 191, pp. 112959-112959
Open Access | Times Cited: 17
A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4
Erik A. Williams, Priscilla K. Brastianos, Hiroaki Wakimoto, et al.
Acta Neuropathologica (2023) Vol. 146, Iss. 3, pp. 515-525
Open Access | Times Cited: 16
Focus on current and emerging treatment options for glioma: A comprehensive review
Brandon Lucke‐Wold, Burhanuddin Sohail Rangwala, Muhammad Ashir Shafique, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 4, pp. 482-495
Open Access | Times Cited: 7
Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks
Lea Stitzlein, Jack T. Adams, Erin N. Stitzlein, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 6
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1466-1477
Open Access | Times Cited: 6
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations
Karthikeyan Murugesan, Andrea Necchi, Timothy C. Burn, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100641-100641
Open Access | Times Cited: 22
From darkness to light: Targeting CAFs as a new potential strategy for cancer treatment
Dong Hua, Weijing Wang, Shuai Liang, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113482-113482
Closed Access | Times Cited: 4
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations
Yasuaki Uemoto, Chang-Ching Lin, Bingnan Wang, et al.
Cancer Letters (2025), pp. 217668-217668
Closed Access
Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
Lauren M. Brown, Paul G. Ekert, Emmy D.G. Fleuren
Oncogene (2023) Vol. 42, Iss. 23, pp. 1875-1888
Open Access | Times Cited: 12
Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3180-3180
Open Access | Times Cited: 16
Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?
Vincenzo Di Nunno, Marta Aprile, Lidia Gatto, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1042-1042
Open Access | Times Cited: 9
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Qingsheng Xu, Kaiyuan Huang, Xiangqi Meng, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 19, pp. 3859-3866
Closed Access | Times Cited: 9
The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer
Majd Al Assaad, Gunes Gundem, Benjamin Liechty, et al.
Molecular Case Studies (2023) Vol. 9, Iss. 4, pp. a006275-a006275
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top